1-8 of 8
Larisa Belyanskaya
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

C1-INH and atiii inhibit vaso-occlusion and vascular inflammation in sickle cell disease mice

Free
John Belcher, Julia Nguyen, Fuad Abdulla, Chunsheng Chen, Conglin Ruan, Larisa Belyanskaya, Sigurd Knaub, Olaf Walter, Gregory Vercellotti
Journal: Blood
Blood (2025) 146 (Supplement 1): 835.
https://doi.org/10.1182/blood-2025-835
Published: 2025
Journal Articles

Impact of secondary FVIII prophylaxis on joint bleeding and arthropathy in a Hemophilia A mouse model lacking inhibitor response

Free
Lara Monica, Joyce Kimenai, Olga Oleshko, Sonja Werwitzke, Lina Aires, Silvio Wuschko, Jonas Füner, Helmut Paul, Enrico Klotzsch, Paul Schauerte, Larisa Belyanskaya, Sander Botter, Andreas Tiede
Journal: Blood
Blood (2025) 146 (Supplement 1): 13.
https://doi.org/10.1182/blood-2025-13
Published: 2025
Journal Articles

Pharmacokinetic-pharmacodynamic modelling of von willebrand factor/factor VIII prophylaxis in von willebrand disease

Free
Ron Mathôt, Robert Sidonio, Jr., Marjon Cnossen, Jelien den Hollander, Sjoerd Koopman, Larisa Belyanskaya, Vincent Milleret
Journal: Blood
Blood (2025) 146 (Supplement 1): 3081.
https://doi.org/10.1182/blood-2025-3081
Published: 2025
Journal Articles

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Free
Ri Liesner, Joris Versteden, Shannely Lowndes, Larisa Belyanskaya, PhD, Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1204.
https://doi.org/10.1182/blood-2018-99-110608
Published: 2018
Journal Articles

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Free
Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD, Susan Halimeh, MD, Robert Klamroth, Joris Versteden, Martina Jansen, Larisa Belyanskaya, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5034.
https://doi.org/10.1182/blood-2018-99-116577
Published: 2018
Journal Articles

Immune Tolerance Induction with Simoctocog Alfa (Nuwiq ® ) in Six Patients with Severe Haemophilia a and FVIII Inhibitors

Free
Neha Bhatnagar, ND, Kate Khair, Ri Liesner, Alice Wilkinson, Larisa Belyanskaya, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5037.
https://doi.org/10.1182/blood-2018-99-118041
Published: 2018
Journal Articles

Budget Impact Analysis of a New-Generation Recombinant Factor VIII from a Human Cell Line (Nuwiq) for the Treatment of Patients with Hemophilia A in Canada

Free
Sri Adapa, BSPharm, MBA, Olga Ovcinnikova, MSc, Ian Leighton, PhD, Shamika de Silva, PhD, Matthew Bending, PhD, Larisa Belyanskaya, PhD, Cosentino Lidia, PhD, Anne Myerson, MSc
Journal: Blood
Blood (2017) 130 (Supplement 1): 4929.
https://doi.org/10.1182/blood.V130.Suppl_1.4929.4929
Published: 2017
Journal Articles

Comparison of the Functional Characteristics and Post-Translational Modifications of Commercial Factor VIII Products

Free
Guido Kohla, PhD, Larisa Belyanskaya, PhD, Maya Tiemeyer, PhD, Thole Züchner, PhD, Irena Knappik, PhD, Julia Rosenlöcher, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2362.
https://doi.org/10.1182/blood.V130.Suppl_1.2362.2362
Published: 2017